CHANGMAO BIO (00954) announced a net loss attributable to shareholders of approximately 66.763 million yuan in 2025, a year-on-year decrease of 2.17%.

22:04 30/03/2026

Changmao Biology (00954) announced its performance in 2025, with revenue of approximately 557 million yuan, a decrease of 4.77% year-on-year; the annual loss attributable to shareholders of the company was 66.763 million yuan, a decrease of 2.17% year-on-year; the loss per share was 0.126 yuan.

CHANGMAO BIO (00954) announced its performance for 2025, with revenue of approximately 557 million yuan, a decrease of 4.77% year-on-year; the annual loss attributable to the company's shareholders was 66.763 million yuan, a 2.17% decrease year-on-year; loss per share was 0.126 yuan.

HEALTHYWAY INC (02587) Achieved Record High Revenue and Profits in 2025, AI Empowers to Build the Core Growth Engine of Enterprise Services.

TSAKER NE (01986) released its annual performance, with a net loss attributable to shareholders of 5.284 million yuan, a year-on-year decrease of 74.96%.

TOMO HOLDINGS (06928) released its annual performance, with a net loss of 3.71 million Singapore dollars, a year-on-year increase of 41.1%.

HEALTHYWAY INC (02587) Achieved Record High Revenue and Profits in 2025, AI Empowers to Build the Core Growth Engine of Enterprise Services.

TSAKER NE (01986) released its annual performance, with a net loss attributable to shareholders of 5.284 million yuan, a year-on-year decrease of 74.96%.

TOMO HOLDINGS (06928) released its annual performance, with a net loss of 3.71 million Singapore dollars, a year-on-year increase of 41.1%.